Asoke K. Mal, PhD, joined the faculty of Roswell Park Comprehensive Cancer Center in 2008 as an Assistant Professor of Oncology in the Department of Cell Stress Biology.
Dr. Mal came to Roswell Park from the Lerner Research Institute, Cleveland Clinic Foundation, OH, where he was on the faculty of the Department of Molecular Genetics. He earned his doctoral degree in 1993 in Biochemistry from the University of Calcutta, India.
Dr. Mal is a member of the American Association of Cancer Research and the American Association for the Advancement of Science. He has authored or co-authored several journal publications.
Dr. Mal’s laboratory focuses on rhabdomyosarcoma (RMS), a family of highly aggressive myogenic soft tissue cancers usually occurring in children and adolescents. Despite intensive traditional multimodal therapy, outcomes for high risk patients with RMS have not significantly improved, and survival of metastatic or relapsed disease remains extremely poor. Specific goals of his research program include the identification of signaling and epigenetic vulnerabilities in RMS and understanding associated molecular mechanisms in order to derive novel therapeutic targets for treatments for these patients. His laboratory uses multidisciplinary approaches involving cell cultures and animal models to study the biological consequence of these events in RMS tumor malignant behaviors. His efforts also involve a drug-discovery approach, where he leverages current understanding of RMS to screen for and identify novel compounds which could be exploited as potential agents in therapeutic intervention for this cancer.
Charles Keller, MD, Children’s Cancer Therapy Development Institute, USA
Mathivan Jothi, PhD, National Institute of Mental Health and Neuroscience (NIMHANS), India
Mukund Seshadri, PhD, DDS, Roswell Park Comprehensive Cancer Center, USA
Eugene Yu, PhD, Roswell Park Comprehensive Cancer Center, USA
Dhyan Chandra, PhD, Roswell Park Comprehensive Cancer Center, USA
Panicker SP, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal AK, Palomo JM, Vogelbaum MA, Haque SJ. p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget 2010; 1(4):289-303
Lee MH, Jothi M, Gudkov AV, Mal AK. Histone Methyltransferase KMT1A Restrains Entry of Alveolar Rhabdomyosarcoma Cells into a Myogenic Differentiated State. Cancer research 2011; 71(11):3921-3931
Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell.Cell cycle (Georgetown, Tex.) 2012; 11(5):895-908
Chatterjee B, Wolff DW, Jothi M, Mal M, Mal AK. P38-MAPK disables KMT1A-mediated repression of myogenic differentiation program, Skeletal Muscle, 2016; Aug 22, 6: 28. PMCID: PMC4993004
Jothi M, Mal M, Keller C, Mal AK. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma. Mol. Cancer Ther., (2013); 12(12), 2663-2674. PMCID: PMC3858449
Jothi M, Nishijo K, Keller C, Mal AK. AKT and PAX3-FKHR cooperation enforces myogenic differentiation blockade in alveolar rhabdomyosarcoma cell. Cell Cycle, 2012:11(5): 895-908. PCMID: PMC3323795
Lee MH, Jothi M, Gudkov AV, Mal AK. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into myogenic differentiated state, Cancer
Res., 2011; 71 (11): 3921-3931. PMCID: PMC3107367